At Seer, we develop innovative solutions that act as a gateway to the proteome. Our goal is to empower the scientific community with tools to achieve exceptional scientific outcomes. We do this by removing the technological barriers that stand between breakthrough ideas and the information that can make them a reality.
Over the last 15 years, the fields of genomics and transcriptomics have undergone an explosion in content and discovery, fueled by massively parallel technologies that made large-scale studies possible and tractable. Advancement in those fields have deepened our understanding of biology and ushered in new treatment mechanisms and diagnostics solutions that impact everyday human life.
Similar capabilities have evaded the field of proteomics. As a result, researchers have been forced into a tradeoff: the scale of the study, or the depth of its coverage. Until now.
We’re committed to eliminating the obstacles that have kept proteomics’ potential from matching the pace of advancements we’ve seen in other fields. We believe that unbiased, deep, rapid, large-scale proteomics can, and must, become accessible to the broad scientific community so that we may significantly advance our understanding of biology, health, and disease. And those studies will require solutions that allow us to accurately survey and analyze the full diversity of proteins across individuals, over time.
Over the last 15 years, the fields of genomics and transcriptomics have undergone an explosion in content and discovery, fueled by massively parallel technologies that made large-scale studies possible and tractable. Advancement in those fields have deepened our understanding of biology and ushered in new treatment mechanisms and diagnostics solutions that impact everyday human life.
Similar capabilities have evaded the field of proteomics. As a result, researchers have been forced into a tradeoff: the scale of the study, or the depth of its coverage. Until now.
We’re committed to eliminating the obstacles that have kept proteomics’ potential from matching the pace of advancements we’ve seen in other fields. We believe that unbiased, deep, rapid, large-scale proteomics can, and must, become accessible to the broad scientific community so that we may significantly advance our understanding of biology, health, and disease. And those studies will require solutions that allow us to accurately survey and analyze the full diversity of proteins across individuals, over time.
Location: United States, California, Redwood City
Employees: 51-200
Phone: +216 98 457 018
Total raised: $110M
Founded date: 2017
Investors 5
| Date | Name | Website |
| - | Old Silver... | oldsilverv... |
| - | aMoon Fund | amoon.fund... |
| - | Mango.vc | mango.vc |
| - | HBM Partne... | hbmpartner... |
| - | Solasta Ve... | solasta-ve... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.09.2020 | - | $55M | - |
| 19.12.2019 | Series D | $55M | aMoon Fund |
Mentions in press and media 7
| Date | Title | Description |
| 13.12.2024 | The Scientist Announces Its 2024 Top 10 Innovations Winners | The Scientist Announces Its 2024 Top 10 Innovations Winners The latest group of winning technologies has a little something for everyone—from scientists at the lab bench to those in the clinic and even the classroom. WILMINGTON, Del., Dec. ... |
| 06.11.2024 | PrognomiQ's $34 Million Boost: A New Dawn for Lung Cancer Detection | In the realm of healthcare, innovation is the lifeblood that fuels progress. PrognomiQ, a rising star in the diagnostics industry, has just secured a significant $34 million in Series D funding. This financial windfall, led by Seer, Inc., m... |
| 05.11.2024 | PrognomiQ Raises $34M to Advance Multi-Omics Early Detection Test for Lung Cancer | What You Should Know: – PrognomiQ, a healthcare company pioneering multi-omics approaches to disease detection, has secured $34M in Series D funding led by Seer, Inc., with participation from a new strategic investor and existing investors ... |
| 15.09.2020 | Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing | - |
| 30.06.2020 | ‘Covid Put Everything On Steroids,’ Says Prominent Healthtech Investor | When VC aMoon was established in 2017, “the premise was to invest heavily in the convergence of technology and biology, healthcare and data,” says Dr. Yair Schindel, its Managing Partner. Schindel and Marius Nacht, the other founder of the ... |
| 19.12.2019 | Seer Announces $55 Million in Series D Equity Financing Bringing in New Investors aMoon Fund and T. Rowe Price Funds | - |
| 17.12.2019 | Seer Raises $55M in Series D Equity Financing | Seer, Inc., a Redwood City, Calif.-based life sciences company focused on capturing and translating proteome insights to advance human health, raised $55m in Series D equity financing. The round was led by healthtech and life sciences ventu... |